Publications - Mark A . Nathan, M.D.

Back to Research Profile

1. Karantanis D, Durski JM, Lowe VJ, Nathan MA, Mullan BP, Georgiou E, Johnston PB, Wiseman GA. (18)F-FDG PET and PET/CT in Burkitt's lymphoma. Eur J Radiol 2009 Aug 26. [Epub ahead of print]
   View PubMed
2. Murphy R, Doerger KM, Nathan MA, Lowe VJ. Pretreatment with diphenoxylate hydrochloride/atropine sulfate (Lomotil) does not decrease physiologic bowel FDG activity on PET/CT scans of the abdomen and pelvis. Mol Imaging Biol 2009 Mar-Apr; 11(2):114-7. Epub 2008 Nov 27.
   View PubMed
3. Bogsrud TV, Karantanis D, Nathan MA, Mullan BP, Wiseman GA, Kasperbauer JL, Reading CC, Hay ID, Lowe VJ. (18)F-FDG PET in the Management of Patients with Anaplastic Thyroid Carcinoma. Thyroid 2008 Jul; 18(7):713-9.
   View PubMed
4. Bogsrud TV, Karantanis D, Nathan MA, Mullan BP, Wiseman GA, Kasperbauer JL, Reading CC, Hay ID, Lowe VJ. 18F-FDG PET in the management of patients with anaplastic thyroid carcinoma. Thyroid 2008 Jul; 18(7):713-9.
   View PubMed
5. Karantanis D, O’Neill BP, Subramaniam RM, Witte RJ, Mullan BP, Nathan MA, Lowe VJ, Peller PJ, Wiseman GA. The value of F-18 FDG PET/CT in primary central nervous system lymphoma in HIV-negative patients. J Nucl Med Commun 2007 Nov; 28(11):834-41.
   View PubMed
6. Karantanis D, O'Neill BP, Subramaniam RM, Witte RJ, Mullan BP, Nathan MA, Lowe VJ, Peller PJ, Wiseman GA. 18F-FDG PET/CT in primary central nervous system lymphoma in HIV-negative patients. Nucl Med Commun 2007 Nov; 28(11):834-41.
   View PubMed
7. Karantanis D, Bogsrud TV, Wiseman GA, Mullan BP, Subramaniam RM, Nathan MA, Peller PJ, Bahn RS, Lowe VJ. Clinical significance of diffusely increased 18F-FDG uptake in the thyroid gland. J Nucl Med 2007 Jun; 48(6):896-901. Epub 2007 May 15.
   View PubMed
8. Karantanis D, Bogsrud TV, Wiseman GA, Mullan BP, Subramaniam RM, Nathan MA, Peller PJ, Bahn RS, Lowe VJ. Clinical significance of diffusely increased 18F-FDG uptake in the thyroid gland. J Nucl Med 2007 Jun; 48(6):896-901.
   View PubMed
9. Bogsrud TV, Karantanis D, Nathan MA, Mullan BP, Wiseman GA, Collins DA, Kasperbauer JL, Strome SE, Reading CC, Hay ID, Lowe VJ. The value of quantifying 18F-FDG uptake in thyroid nodules found incidentally on whole-body PET-CT. Nucl Med Commun 2007 May; 28(5):373-81.
   View PubMed
10. Christensen JA, Nathan MA, Mullan BP, Hartman TE, Swensen SJ, Lowe VJ. Characterization of the solitary pulmonary nodule: 18F-FDG PET versus nodule-enhancement CT. AJR Am J Roentgenol 2006 Nov; 187(5):1361-7.
    View PubMed
11. Lowe VJ, Booya F, Fletcher JG, Nathan M, Jensen E, Mullan B, Rohren E, Wiersema MJ, Vazquez-Sequeiros E, Murray JA, Allen MS, Levy MJ, Clain JE. Comparison of positron emission tomography, computed tomography, and endoscopic ultrasound in the initial staging of patients with esophageal cancer. Molecular Imaging & Biology 2005 Nov-Dec; 7(6):422-30.
    View PubMed
12. Lindell RM, Hartman TE, Swensen SJ, Jett JR, Midthun DE, Nathan MA, Lowe VJ. Lung cancer screening experience: A retrospective review of PET in 22 non-small cell lung carcinomas detected on screening chest CT in a high-risk population. Am J Roentgenol 2005 Jul; 185(1):126-31.
    View PubMed
13. Foley TA, Earnest F IV, Nathan MA, Hough DM, Schiller HJ, Hoskin TL. Differentiation of non-perforated and perforated appendicitis: accuracy of CT diagnosis and relationship of CT findings to hospital length of stay. Radiology 2005 Apr; 235(1):89-96.
14. Gangi S, Fletcher JG, Nathan MA, Christensen JA, Harmsen WS, Crownhart BS, Chari ST. Time interval between abnormalities seen on CT and the clinical diagnosis of pancreatic cancer: Retrospective review of CT scans obtained before diagnosis. Am J Roentgenol 2004 Apr; 182(4):897-903.
    View PubMed
15. Bushnell DL, Madsen M, Kahn D, Nathan M, Williams RD. Enhanced uptake of 99Tcm-MDP in skeletal metastases from prostate cancer following initiation of hormone treatment: Potential for increasing delivery of therapeutic agents. Nucl Med Commun 1999; 20:875-81.
    View PubMed
16. Nathan MA, Abu-Yousef MM. The "vascular pedicle sign" in the diagnosis of pelvic masses. JDMS 1997; 13:28-31.
17. Murphy SP, Nathan MA, Karwal MW. FDG-PET appearance of pelvic Castleman's disease: Correlation with CT. J Nucl Med 1997; 38:1211-12.
    View PubMed
18. Nathan MA, Seabold JE, Brown BP, Bushnell DL. Colonic localization of labeled leukocytes in critically ill patients: Scintigraphic detection of pseudomembranous colitis. Clin Nucl Med 1995; 20:99-106.
    View PubMed
19. Varney NR, Bushnell DL, Nathan MA, Kahn D, Roberts R, Rezai K, Walker W, Kirchner PT. NeuroSPECT correlates of disabling mild head injury: Preliminary findings. J Head Trauma Rehabilitation 1995; 10:18-28.
20. Kahn D, Follett KA, Bushnell DL, Nathan MA, Piper JG, Madsen MT, Kirchner PT. Diagnosis of recurrent brain tumor: Value of 201T1 SPECT vs 18F-fluorodeoxyglucose PET. AJR 1994; 163:1459-65.
    View PubMed
21. Cook EH, Metz JT, Leventhal B, Lebovitz M, Nathan M, Semerdjian SA, et al. Fluoxetine effects on cerebral glucose metabolism. Neuroreport 1994; 5:1745-8.
    View PubMed
22. Nathan MA, Bushnell DL, Kahn D, Simonson TM, Kirchner PT. Crossed cerebellar diaschisis associated with balloon occlusion of the carotid artery. Nucl Med Commun 1994; 15:448-54.
    View PubMed
23. Madsen MT, Kirchner PT, Edlin JP, Nathan MA, Kahn D. An emission-based technique for obtaining attenuation correction data for myocardial SPECT studies. Nucl Med Commun 1993; 14:689-95.
    View PubMed
24. Bogsrud TV, Karantanis D, Nathan MA, Mullan BP, Wiseman GA, Collins DA, Kasperbauer JL, Strome SE, Reading CC, Hay ID, Lowe VJ. The value of quantifying 18F-FDG uptake in thyroid nodules found incidentally on whole body PET-CT. Nucl Med Commun 2007 May; 28(5):373-381.
    View PubMed